Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Natural killer (NK) cells are considered a promising tool for adoptive immunotherapy due to their capacity to spontaneously kill tumor cells without prior sensitization. However, due to the low expansion rate, exhausted phenotype and scale expansion issues, it is challenging to transfer the bench-top expansion protocols to clinically applicable methods for NK cell-based therapy.
At Creative Biolabs, we have developed several novel NK expansion technologies for large-scale NK cell expansion processes. Our NK cell expansion platform enables the expansion of NK cells from peripheral blood mononuclear cells (PBMCs) and CB (cord blood). These expanded cells demonstrated increased persistence, proliferation, and function and were ready for preclinical and clinical applications.
Expansion of NK cells for clinical use requires a large cell dose and requires appropriate activity and modification to have better anti-tumor function. There are many validated protocols for the expansion of NK cells ex vivo, all of which have specific characteristics and functions. At Creative Biolabs, we provide a comprehensive overview of starting materials and culture conditions, the key cytokines, feeder cells, and culture additives to develop viable NK expansion strategies to meet the needs of customers. Currently, we provide the following strategies to obtain the appropriate amount of functional NK cells:
Fig.1 Regular ex vivo NK activation and expansion procedures.1
NK cells can be expanded from human PBMC or isolated NK cells. Our defined NK medium enables a high expansion rate, leading to long-term in vivo persistence and enhanced effector functions of the NK cell population. Generally, our NK cell expansion process can be divided into the following steps:
If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
